Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT). Cook G, et al. Among authors: morris e. Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006. Epub 2010 Apr 24. Biol Blood Marrow Transplant. 2010. PMID: 20399879 Free article.
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K. Peggs KS, et al. Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Free article. Clinical Trial.
Reduced intensity transplantation: where are we now?
Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS. Mackinnon S, et al. Among authors: morris e. Hematol J. 2004;5 Suppl 3:S34-8. doi: 10.1038/sj.thj.6200419. Hematol J. 2004. PMID: 15190275 Review. No abstract available.
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Morris E, et al. Blood. 2004 Dec 15;104(13):3865-71. doi: 10.1182/blood-2004-03-1105. Epub 2004 Aug 10. Blood. 2004. PMID: 15304395 Free article.
2,174 results